-
Something wrong with this record ?
Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
K. Mitrova, B. Pipek, M. Bortlik, L. Bouchner, J. Brezina, T. Douda, T. Drasar, P. Drastich, P. Falt, P. Klvana, V. Leksa, A. Novotny, P. Svoboda, J. Skorpik, J. Ulbrych, M. Veinfurt, B. Zborilova, M. Lukas, D. Duricova
Language English Country Great Britain
Document type Journal Article
NLK
Directory of Open Access Journals
from 2018
Free Medical Journals
from 2008
PubMed Central
from 2008
Europe PubMed Central
from 2008
ProQuest Central
from 2017-01-01
Health & Medicine (ProQuest)
from 2017-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2008
- Publication type
- Journal Article MeSH
Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of ustekinumab seems to have a pattern similar to anti-tumour necrosis factor agents. Current evidence on the placental pharmacokinetics of vedolizumab and ustekinumab is limited. We aimed to assess the placental transfer of ustekinumab and vedolizumab in pregnant patients with inflammatory bowel disease. Methods: Consecutive women from a prospective observational study who were exposed to ustekinumab or vedolizumab within 2 months prior to conception or during pregnancy were included. Ustekinumab and vedolizumab levels were measured in maternal and cord blood at the time of delivery. Results: Drug levels were available in 31 infant-mother pairs (15 exposed to ustekinumab and 16 to vedolizumab). The median maternal and newborn ustekinumab levels were 5.3 mg/l and 10.3 mg/l, respectively (the median infant-to-maternal ratio was 1.7), while the median maternal and cord vedolizumab levels were 7.3 mg/l and 4.5 mg/l (the median infant-to-maternal ratio was 0.66). The ustekinumab levels in cord blood positively correlated with the maternal levels at delivery (ρ = 0.751, p = 0.001). However, no correlation with the timing of the last drug administration was found. In contrast, the vedolizumab levels in cord blood demonstrated significant positive correlation with the maternal levels (ρ = 0.831, p < 0.001) along with the gestational week of the last infusion (ρ = 0.736, p = 0.001). Conclusion: Vedolizumab demonstrated different placental pharmacokinetics, leading to lower drug levels in cord blood compared to maternal blood at delivery; in contrast, the placental transfer of ustekinumab seems to have a pattern similar to anti-tumour necrosis factor (TNF) agents.
2nd Department of Internal Medicine St Anne's University Hospital Brno Brno střed Czech Republic
4th Internal Clinic General University Hospital Charles University Prague Czech Republic
Beskydy Gastrocentre Hospital Frýdek Místek Frýdek Czech Republic
Department of Gastroenterology Hospital České Budejovice
Department of Gastroenterology Hospital Jihlava Jihlava Czech Republic
Department of Gastroenterology Hospital Karlovy Vary Karlovy Vary Karlovarský Czech Republic
Department of Internal Medicine Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Internal Medicine University Hospital Plzen Bory UK
Endoscopy Internal Department Pardubice Hospital Pardubice Czech Republic
IBD Center Turnov Liberec Regional Hospital Liberec Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024193
- 003
- CZ-PrNML
- 005
- 20211013134025.0
- 007
- ta
- 008
- 211006s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/17562848211032790 $2 doi
- 035 __
- $a (PubMed)34394725
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mitrova, Katarina $u Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
- 245 10
- $a Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study / $c K. Mitrova, B. Pipek, M. Bortlik, L. Bouchner, J. Brezina, T. Douda, T. Drasar, P. Drastich, P. Falt, P. Klvana, V. Leksa, A. Novotny, P. Svoboda, J. Skorpik, J. Ulbrych, M. Veinfurt, B. Zborilova, M. Lukas, D. Duricova
- 520 9_
- $a Background: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of ustekinumab seems to have a pattern similar to anti-tumour necrosis factor agents. Current evidence on the placental pharmacokinetics of vedolizumab and ustekinumab is limited. We aimed to assess the placental transfer of ustekinumab and vedolizumab in pregnant patients with inflammatory bowel disease. Methods: Consecutive women from a prospective observational study who were exposed to ustekinumab or vedolizumab within 2 months prior to conception or during pregnancy were included. Ustekinumab and vedolizumab levels were measured in maternal and cord blood at the time of delivery. Results: Drug levels were available in 31 infant-mother pairs (15 exposed to ustekinumab and 16 to vedolizumab). The median maternal and newborn ustekinumab levels were 5.3 mg/l and 10.3 mg/l, respectively (the median infant-to-maternal ratio was 1.7), while the median maternal and cord vedolizumab levels were 7.3 mg/l and 4.5 mg/l (the median infant-to-maternal ratio was 0.66). The ustekinumab levels in cord blood positively correlated with the maternal levels at delivery (ρ = 0.751, p = 0.001). However, no correlation with the timing of the last drug administration was found. In contrast, the vedolizumab levels in cord blood demonstrated significant positive correlation with the maternal levels (ρ = 0.831, p < 0.001) along with the gestational week of the last infusion (ρ = 0.736, p = 0.001). Conclusion: Vedolizumab demonstrated different placental pharmacokinetics, leading to lower drug levels in cord blood compared to maternal blood at delivery; in contrast, the placental transfer of ustekinumab seems to have a pattern similar to anti-tumour necrosis factor (TNF) agents.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pipek, Barbora $u Digestive Diseases Center, Hospital AGEL Vitkovice, Zaluzanskeho 1192/15, Ostrava Vítkovice, 700 30, Czech Republic
- 700 1_
- $a Bortlik, Martin $u Department of Gastroenterology, Hospital České Budejovice
- 700 1_
- $a Bouchner, Ludek $u Department of Internal Medicine, University Hospital Plzen Bory, UK
- 700 1_
- $a Brezina, Jan $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Douda, Tomas $u 2nd Department of Gastroenterology, Faculty of Medicine and Dentistry, Charles University and University Hospital Hradec Králové, Czech Republic
- 700 1_
- $a Drasar, Tomas $u IBD Center Turnov, Liberec Regional Hospital, Liberec, Czech Republic
- 700 1_
- $a Drastich, Pavel $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Falt, Premysl $u 2nd Department of Internal Medicine - Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Czech Republic
- 700 1_
- $a Klvana, Pavel $u Beskydy Gastrocentre, Hospital Frýdek-Místek, Frýdek, Czech Republic
- 700 1_
- $a Leksa, Vaclav $u Endoscopy, Internal Department, Pardubice Hospital, Pardubice, Czech Republic
- 700 1_
- $a Novotny, Ales $u 4th Internal Clinic, General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Svoboda, Pavel $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Skorpik, Jan $u Department of Gastroenterology, Hospital Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Ulbrych, Jan $u 2nd Department of Internal Medicine, St. Anne's University Hospital Brno, Brno-střed, Czech Republic
- 700 1_
- $a Veinfurt, Marek $u Department of Gastroenterology, Hospital Karlovy Vary, Karlovy Vary, Karlovarský, Czech Republic
- 700 1_
- $a Zborilova, Blanka $u Department of Gastroenterology, Hospital Karlovy Vary, Karlovy Vary, Karlovarský, Czech Republic
- 700 1_
- $a Lukas, Milan $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Duricova, Dana $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE a.s., Charles University in Prague, Czech Republic
- 773 0_
- $w MED00177174 $t Therapeutic advances in gastroenterology $x 1756-283X $g Roč. 14, č. - (2021), s. 17562848211032790
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34394725 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013134023 $b ABA008
- 999 __
- $a ind $b bmc $g 1708228 $s 1144690
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 14 $c - $d 17562848211032790 $e 20210807 $i 1756-283X $m Therapeutic advances in gastroenterology $n Therap Adv Gastroenterol $x MED00177174
- LZP __
- $a Pubmed-20211006
